CompletedNCT05061706
Lumateperone added to antidepressants for persistent depression
About this title
Read the official source — NCT05061706This study evaluated the safety and effectiveness of Lumateperone for people with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Lumateperone for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 30, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 480
- Sponsor
- Intra-Cellular Therapies, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Argentina, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05061706
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Rogers, United States · Newport Beach, United States
40 more locations
- Riverside, United States
- San Diego, United States
- Palm Bay, United States
- West Palm Beach, United States
- Atlanta, United States
- Overland Park, United States
- Gaithersburg, United States
- Flowood, United States
- Brooklyn, United States
- Charlotte, United States
- Allentown, United States
- Media, United States
- Plymouth Meeting, United States
- Bellevue, United States
- Buenos Aires, Argentina
- Córdoba, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Helsinki, Finland
- Oulu, Finland
- Bad Homburg, Germany
- Freiburg im Breisgau, Germany
- Hamburg, Germany
- Mittweida, Germany
- Schwerin, Germany
- Westerstede, Germany
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Gorlice, Poland
- Leszno, Poland
- Pruszcz Gdański, Poland
- Torun, Poland
- Wroclaw, Poland
- Lund, Sweden
- Stockholm, Sweden
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Lumateperone for people with depression.
Who is behind this study?
The study sponsor is Intra-Cellular Therapies, Inc.
Did this study involve medication?
Yes. The study involved medication, including Lumateperone and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
